

# Rodrigo Martino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/68692/publications.pdf>

Version: 2024-02-01

149  
papers

5,255  
citations

145106

33  
h-index

104191

69  
g-index

152  
all docs

152  
docs citations

152  
times ranked

5996  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	2.5	5
2	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	2.5	35
3	SARS-CoV-2 reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. <i>American Journal of Hematology</i> , 2022, 97, 30-42.	2.0	52
4	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2022, 63, 538-550.	0.6	8
5	Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 43.e1-43.e5.	0.6	10
6	Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 282-285.	1.3	10
7	Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with <i>FGFR1</i> -rearrangement: a study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 416-422.	1.3	11
8	Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. <i>Blood Advances</i> , 2022, 6, 848-853.	2.5	5
9	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. <i>Journal of Hematology and Oncology</i> , 2022, 15, 54.	6.9	26
10	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 681-693.	0.6	13
11	Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. <i>Annals of Hematology</i> , 2022, 101, 2053-2067.	0.8	7
12	Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry. <i>Bone Marrow Transplantation</i> , 2022, 57, 1531-1538.	1.3	5
13	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	0.6	15
14	Analysis of Cell Subsets in Donor Lymphocyte Infusions from HLA Identical Sibling Donors after Allogeneic Hematopoietic Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 53.e1-53.e8.	0.6	3
15	Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching. <i>Bone Marrow Transplantation</i> , 2021, 56, 818-827.	1.3	30
16	Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 493.e1-493.e8.	0.6	5
17	A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. <i>EClinicalMedicine</i> , 2021, 33, 100787.	3.2	14
18	Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2021, 56, 2432-2444.	1.3	33

#	ARTICLE	IF	CITATIONS
19	Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2021, 15, 326.	0.4	8
20	Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?. <i>Bone Marrow Transplantation</i> , 2021, 56, 2489-2496.	1.3	15
21	Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 614.e1-614.e8.	0.6	2
22	Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2904-2910.	1.3	7
23	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	1.3	13
24	COVID-19 in Children Following Hematopoietic Cell Transplantation: A Multinational Study of the European Bone Marrow Transplantation Society (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). <i>Blood</i> , 2021, 138, 2866-2866.	0.6	4
25	Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT. <i>Journal of Neurology</i> , 2020, 267, 430-439.	1.8	13
26	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2020, 3, e1918668.	2.8	40
27	When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine). <i>Annals of Hematology</i> , 2020, 99, 157-165.	0.8	7
28	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	2.5	18
29	Intercontinental study on pre-engraftment and post-engraftment Gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: Risk factors and association with mortality. <i>Journal of Infection</i> , 2020, 81, 882-894.	1.7	9
30	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1823-1832.	0.6	1
31	Risk factors and outcome of COVID-19 in patients with hematological malignancies. <i>Experimental Hematology and Oncology</i> , 2020, 9, 21.	2.0	119
32	Living donor kidney transplantation is an effective option of renal replacement therapy in patients with light-chain amyloidosis (AL). <i>Annals of Hematology</i> , 2020, 99, 2961-2962.	0.8	1
33	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	0.8	36
34	Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19. <i>Annals of Hematology</i> , 2020, 99, 1673-1674.	0.8	56
35	Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002-2018 Empirical/Pre-emptive Approach. <i>Mycopathologia</i> , 2020, 185, 639-652.	1.3	0
36	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35

#	ARTICLE	IF	CITATIONS
37	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
38	Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas. <i>International Journal of Hematology</i> , 2019, 110, 406-410.	0.7	4
39	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2398-2407.	2.0	21
40	Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients. <i>European Journal of Haematology</i> , 2019, 103, 208-214.	1.1	9
41	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58
42	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
43	Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH). <i>European Journal of Haematology</i> , 2019, 102, 465-471.	1.1	18
44	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	2.5	71
45	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	2.5	89
46	Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1133-1137.	1.3	0
47	Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1022-1030.	2.0	11
48	CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 143-148.	0.7	26
49	Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. <i>European Journal of Haematology</i> , 2019, 102, 79-86.	1.1	14
50	Clinical Validation of the Myelofibrosis Transplant Scoring System in an Independent Series of Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Transplantation. <i>Blood</i> , 2019, 134, 5733-5733.	0.6	2
51	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 945-955.	2.0	7
52	Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. <i>Medical Oncology</i> , 2018, 35, 79.	1.2	15
53	Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 146-154.	0.6	17
54	Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 55-63.	2.0	33

#	ARTICLE	IF	CITATIONS
55	Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis. <i>Bone Marrow Transplantation</i> , 2018, 53, 1478-1482.	1.3	7
56	Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 737-742.	0.2	1
57	Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2018, 101, 407-414.	1.1	7
58	Efficacy and safety of native versus pegylated <i>Escherichia coli</i> asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1634-1643.	0.6	13
59	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	0.6	278
60	Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases. <i>Annals of Hematology</i> , 2017, 96, 787-796.	0.8	3
61	A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1177-1185.	2.0	22
62	Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. <i>Annals of Hematology</i> , 2017, 96, 1069-1075.	0.8	21
63	Fc $\gamma$ RIIb expression in early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2642-2648.	0.6	7
64	Do Patients and Physicians Agree When They Assess Quality of Life?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1005-1010.	2.0	12
65	Improved survival after acute graft-versus-host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	1.7	79
66	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	0.6	210
67	Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 491-497.	2.0	37
68	Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. <i>Blood Advances</i> , 2017, 1, 1047-1055.	2.5	6
69	Cord Blood Units with High CD3 + Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cell-Depleted Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1073-1079.	2.0	11
70	Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1808-1815.	2.0	29
71	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
72	Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. <i>European Journal of Haematology</i> , 2016, 96, 128-135.	1.1	19

#	ARTICLE	IF	CITATIONS
73	Frequency and Prognostic Significance of the Presence of Additional Cytogenetic Abnormalities (ACA) to the Philadelphia (Ph) Chromosome in Young Adults with ACUTE Lymphoblastic Leukemia (ALL) Treated with the ALL Ph08 Trial from the Pethema Group. <i>Blood</i> , 2016, 128, 1602-1602.	0.6	0
74	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1746-1753.	2.0	48
75	Few and Nonsevere Adverse Infusion Events Using an Automated Method for Diluting and Washing before Unrelated Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 682-687.	2.0	7
76	Post-Thaw Viable CD45 + Cells and Clonogenic Efficiency are Associated with Better Engraftment and Outcomes after Single Cord Blood Transplantation in Adult Patients with Malignant Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2167-2172.	2.0	17
77	Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2812-2818.	0.6	5
78	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
79	Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the Pethema ALL-HR-11 Trial. <i>Blood</i> , 2015, 126, 1333-1333.	0.6	9
80	Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain. <i>Blood</i> , 2015, 126, 2723-2723.	0.6	1
81	An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 3142-3142.	0.6	0
82	The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma. <i>Blood</i> , 2015, 126, 2007-2007.	0.6	0
83	Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Mediators of Inflammation</i> , 2014, 2014, 1-7.	1.4	16
84	Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 66-72.	2.0	41
85	Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2014, 124, 422-422.	0.6	6
86	Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome. <i>Blood</i> , 2014, 124, 1165-1165.	0.6	0
87	Molecular diagnosis of bloodstream infections with a new dual-priming oligonucleotide-based multiplex PCR assay. <i>Journal of Medical Microbiology</i> , 2013, 62, 1673-1679.	0.7	49
88	The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycophenolate. <i>Haematologica</i> , 2013, 98, 526-532.	1.7	30
89	The Presence Of 1 / 8 HLA Mismatch Do Not Hamper Survival After Allogeneic Stem Cell Transplantation Using Immunoprophylaxis With Sirolimus-Tacrolimus. <i>Blood</i> , 2013, 122, 4529-4529.	0.6	0
90	Long-Term Follow-Up Of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation For High Risk Follicular Lymphoma. <i>Blood</i> , 2013, 122, 5519-5519.	0.6	0



#	ARTICLE	IF	CITATIONS
91	Identification Of Patients At High Risk Of Chronic Graft-Versus-Host Disease: Gvhd Prophylaxis. Blood, 2013, 122, 4611-4611.	0.6	0
92	The Combination of the EBMT Score and the HCT-CI Is Not Better Than the HCT-CI Alone in the Prediction of NRM and OS in Patients Undergoing Allogeneic Hematopoietic Transplantation with Reduced-Toxicity Conditioning. Blood, 2012, 120, 1925-1925.	0.6	0
93	Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica, 2011, 96, 291-297.	1.7	51
94	Improved Response to 5-Azacytidine in Patients with Primary Compared to Secondary AML, Particularly If NPM1 Mutations Are Present,. Blood, 2011, 118, 3562-3562.	0.6	0
95	The Combination of Siromilus Plus Tacrolimus (SiTac) Improves the Results of Cyclosporine Plus Mycophenolate Mofetil (CsAMMF) After Reduced Intensity Conditioning (RIC) Unrelated Donor Allogeneic Transplantation. Blood, 2011, 118, 890-890.	0.6	0
96	5-Azacytidine Before or After Stem Cell Transplantation in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndromes (MDS). Blood, 2011, 118, 4267-4267.	0.6	0
97	Clofarabine-Based Chemotherapy for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. the Spanish Experience. Blood, 2011, 118, 4246-4246.	0.6	0
98	Phase I/II Clinical Trial for the Evaluation of Bortezomib within the Reduced Intensity Conditioning Regimen (RIC) and Post-Allogeneic Transplantation As Gvhd Prophylaxis Among High-Risk Myeloma Patients. EudraCT: 2005â€œ004858-27. Blood, 2011, 118, 3025-3025.	0.6	0
99	Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 405-411.	0.8	285
100	Hepatic Toxicity After Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation: Incidence, Characteristics and Risk Factors In a Cohort of 452 Patients.. Blood, 2010, 116, 3495-3495.	0.6	0
101	Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Singleâ€œcenter analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. American Journal of Hematology, 2009, 84, 571-578.	2.0	43
102	Reducing the Risk for Transplant Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?.. Blood, 2009, 114, 649-649.	0.6	2
103	Association Between the Hematopoietic Cell Transplantation-Specific Comorbidity Index (CI) and Non-Relapse Mortality (NRM) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).. Blood, 2009, 114, 650-650.	0.6	3
104	The Role of In Vivo T-Cell Depletion On Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation From HLA-Identical Siblings in Patients with Follicular Lymphoma: An European Blood and Marrow Transplantation Study.. Blood, 2009, 114, 3375-3375.	0.6	0
105	Intrathecal Liposomal Cytarabine (DepoCytâ€œ) for Treatment of Leptomeningeal Involvement From Transformed (Richter's syndrome) and Non-Transformed B-Cell Chronic Lymphocytic Leukemia (B-CLL) in Spain: Report of 8 Cases.. Blood, 2009, 114, 4411-4411.	0.6	4
106	Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival. Journal of Clinical Oncology, 2008, 26, 577-584.	0.8	213
107	Validation of Comorbidity Indexes in Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation. the Hematopoietic Cell Transplantation Comorbidity Index Is the Best Predictor of NRM and Survival.. Blood, 2008, 112, 3277-3277.	0.6	2
108	Immune Response to the 23-Valent Polysaccharide Pneumococcal Vaccine (PPV23) after the 7-Valent Conjugate Vaccine (PCV7) in Allogeneic Stem Cell Transplant (SCT) Recipients: Results of the EBMT IDWP01 Trial. Blood, 2008, 112, 350-350.	0.6	5

#	ARTICLE	IF	CITATIONS
109	Treatment of Chronic Myeloid Leukemia with Imatinib. A Single Centre Experience. <i>Blood</i> , 2008, 112, 4289-4289.	0.6	0
110	Long Term Results of Fludarabine/Melphalan as Reduced Intensity Conditioning Regimen (RIC) for Transplantation in Mantle Cell Lymphoma (MCL): Age Matters. <i>Blood</i> , 2008, 112, 4388-4388.	0.6	0
111	Targeting the Poor Mobilizing Population of Patients for An Autologous Transplantation Procedure: A Single Centre Experience. <i>Blood</i> , 2008, 112, 4136-4136.	0.6	0
112	Cyclosporine a and Mycophenolate Mofetil Vs Cyclosporine a and Methotrexate as Gvhd Prophylaxis in Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donor.. <i>Blood</i> , 2008, 112, 2229-2229.	0.6	0
113	Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis.. <i>Blood</i> , 2007, 110, 47-47.	0.6	5
114	Anti-Thymocyte Globulin Induces Higher Response Rates and Less Graft-Versus-Host Disease in Multiple Myeloma Patients Undergoing Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 2980-2980.	0.6	1
115	Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Using Oral Fludarabine as Part of the Conditioning Regimen.. <i>Blood</i> , 2007, 110, 4925-4925.	0.6	0
116	Comparison of Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate in Reduced Intensity Conditioning HLA Sibling Allogeneic Stem Cell Transplantation. A Case-Match Single-Center Experience.. <i>Blood</i> , 2007, 110, 4994-4994.	0.6	0
117	The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007, 110, 3014-3014.	0.6	0
118	Severe Infections after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation in Adults: Comparison of Cord Blood Transplantation with Peripheral Blood and Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 734-748.	2.0	180
119	Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. <i>Blood</i> , 2006, 108, 836-846.	0.6	337
120	Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2006, 108, 2928-2936.	0.6	129
121	Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. <i>British Journal of Haematology</i> , 2006, 132, 138-154.	1.2	46
122	Impact of Cytogenetics on Outcome of Patients with MDS or Secondary AML Undergoing Allogeneic HSCT from HLA-Identical Siblings: A Retrospective Analysis of the EBMT-CLWP.. <i>Blood</i> , 2006, 108, 2653-2653.	0.6	5
123	Long Remission Are Possible after Non Myeloablative Transplant in Patients with Follicular Non-Hodgkinâ€™s Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.. <i>Blood</i> , 2006, 108, 3024-3024.	0.6	0
124	Fludarabine and Busuphan (Flu-Bu) as Reduced Intensity-Conditioning (RIC) Regimen in HLA-Identical Sibling Allogeneic Hematopoietic Stem Transplantation (Allo-SCT) for Myeloid Malignancies. Results of a Prospective Multicenter Study.. <i>Blood</i> , 2006, 108, 5363-5363.	0.6	0
125	Early Detection of Toxoplasma Infection by Molecular Monitoring of Toxoplasma gondii in Peripheral Blood Samples after Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2005, 40, 67-78.	2.9	221
126	Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies. <i>Leukemia and Lymphoma</i> , 2005, 46, 1429-1435.	0.6	24



#	ARTICLE	IF	CITATIONS
127	Reduced-Intensity Conditioning Allogeneic Blood Stem Cell Transplantation with Fludarabine and Oral Busulfan with or without Pharmacokinetically Targeted Busulfan Dosing in Patients with Myeloid Leukemia Ineligible for Conventional Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 437-447.	2.0	26
128	Prospective Study of the Incidence, Clinical Features, and Outcome of Symptomatic Upper and Lower Respiratory Tract Infections by Respiratory Viruses in Adult Recipients of Hematopoietic Stem Cell Transplants for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 781-796.	2.0	200
129	Allogeneic Myelo-Ablative Stem Cell Transplant (SCT) as Salvage Therapy of Reduced-Intensity Conditioned (RIC) SCT: Toxicity and Outcome.. <i>Blood</i> , 2005, 106, 3666-3666.	0.6	5
130	Impact of Dendritic Cell CD16+ Recovery on Outcome after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 1409-1409.	0.6	0
131	Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. <i>Current Medical Research and Opinion</i> , 2004, 20, 485-504.	0.9	35
132	Blastoschizomyces capitatus Infection in Patients with Leukemia: Report of 26 Cases. <i>Clinical Infectious Diseases</i> , 2004, 38, 335-341.	2.9	108
133	Low-dose amphotericin b lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - a randomized, controlled trial. <i>European Journal of Haematology</i> , 2004, 72, 342-347.	1.1	66
134	Influence of the Intensity of the Conditioning Regimen on the Characteristics of Acute and Chronic Graft Versus Host Disease after Allogeneic Transplantation.. <i>Blood</i> , 2004, 104, 5157-5157.	0.6	0
135	No Signs of New Toxicity When Amphotericin B Lipid Complex (ABLC, ABELCET) and Caspofungin Are Used in Combination in the Treatment of FUO.. <i>Blood</i> , 2004, 104, 5077-5077.	0.6	1
136	Respiratory Virus Infections in Adults with Hematologic Malignancies: A Prospective Study. <i>Clinical Infectious Diseases</i> , 2003, 36, 1-8.	2.9	111
137	Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. <i>Haematologica</i> , 2003, 88, 555-60.	1.7	91
138	Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. <i>Blood</i> , 2002, 100, 2243-2245.	0.6	167
139	Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. <i>British Journal of Haematology</i> , 2002, 116, 475-482.	1.2	200
140	Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. <i>Haematologica</i> , 2002, 87, 528-34.	1.7	36
141	Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. <i>Haematologica</i> , 2002, 87, 822-7.	1.7	28
142	Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. <i>British Journal of Haematology</i> , 2001, 115, 653-659.	1.2	102
143	Intensified Prophylaxis of Febrile Neutropenia with Ofloxacin Plus Rifampin During Severe Short-Duration Neutropenia in Patients with Lymphoma. <i>Leukemia and Lymphoma</i> , 1999, 34, 585-589.	0.6	8
144	Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 569-572.	1.3	19

#	ARTICLE	IF	CITATIONS
145	Autologous or Allogeneic Stem Cell Transplantation in Advanced Low-Grade Lymphomas?. Blood, 1998, 91, 4810-4811.	0.6	0
146	Listeriosis in Bone Marrow Transplant Recipients. Clinical Infectious Diseases, 1996, 23, 419-420.	2.9	13
147	Hematopoietic growth factor (G-CSF or GM-CSF) after salvage chemotherapy in refractory or relapsed adult de novo acute leukemia. Leukemia and Lymphoma, 1996, 20, 321-326.	0.6	3
148	Infection by <i>Listeria monocytogenes</i> in the early period post bone marrow transplantation. European Journal of Haematology, 1994, 53, 251-252.	1.1	3
149	Treatment of Refractory and Relapsed Adult Acute Leukemia Using a Uniform Chemotherapy Protocol. Leukemia and Lymphoma, 1993, 11, 393-398.	0.6	7